BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license

Reuters

Sep 26, 2025

** Australia's INOVIQ IIQ.AX jumps as much as 10% to A$0.44

** Stock gains 5% so far this week; set for second straight week of gains

** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer

** Around 178,990 shares traded, 1.8x the 30-day average

** IIQ last up 3.8%, trims YTD losses to 19.4%

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570025247"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570025247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570025247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 08:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570025247","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license</title></head><body><p>** Australia's INOVIQ <span>IIQ.AX</span> jumps as much as 10% to A$0.44</p><p>** Stock gains 5% so far this week; set for second straight week of gains</p><p>** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer</p><p>** Around 178,990 shares traded, 1.8x the 30-day average</p><p>** IIQ last up 3.8%, trims YTD losses to 19.4%</p><p> (Reporting by Roshan Thomas in Bengaluru)</p><p> ((Roshan.Thomas@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-26 08:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license</title></head><body><p>** Australia's INOVIQ <span>IIQ.AX</span> jumps as much as 10% to A$0.44</p><p>** Stock gains 5% so far this week; set for second straight week of gains</p><p>** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer</p><p>** Around 178,990 shares traded, 1.8x the 30-day average</p><p>** IIQ last up 3.8%, trims YTD losses to 19.4%</p><p> (Reporting by Roshan Thomas in Bengaluru)</p><p> ((Roshan.Thomas@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IIQ.AU","symbol_name":"INOVIQ LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nL3N3VD00N:1","article_id":"2570025247","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570025247","pubTimestamp":1758847250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license** Australia's INOVIQ IIQ.AX jumps as much as 10% to A$0.44** Stock gains 5% so far this week; set for second straight week of gains** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer** Around 178,990 shares traded, 1.8x the 30-day average** IIQ last up 3.8%, trims YTD losses to 19.4%  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IIQ.AU":"INOVIQ LTD","BK7124":"保健护理服务"},"translate_title":"BUZZ-澳大利亚INOVIQ获得卵巢癌生物标志物许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IIQ.AU":0.9},"content_text":"BUZZ-Australia's INOVIQ jumps on ovarian cancer biomarker license** Australia's INOVIQ IIQ.AX jumps as much as 10% to A$0.44** Stock gains 5% so far this week; set for second straight week of gains** Biotech firm secures exclusive worldwide licence from University of Queensland's commercialisation company UniQuest to develop, commercialise novel exosomal biomarkers for early detection of ovarian cancer** Around 178,990 shares traded, 1.8x the 30-day average** IIQ last up 3.8%, trims YTD losses to 19.4% (Reporting by Roshan Thomas in Bengaluru) ((Roshan.Thomas@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}